SlideShare a Scribd company logo
Heart failure
What is Heart Failure?
A symptom complex due to
the inability of the heart to
function efficiently as a
pump - there is a
disproportion between the
hemodynamic demand and
the capacity of the heart to
handle the demand
( Supply ≠ Demand)
Heart Failure
• Heart failure occurs when cardiac
output is inadequate to provide the
oxygen needed by the body.
• It is a highly lethal condition, with a 5-
year mortality rate conventionally said to
be about 50%.
• The most common cause of heart
failure is coronary artery disease.
If Heart does not contract well (systolic
HF) traffic (blood) piles up before the
heart (lungs and periphery).
Role of physiologic compensatory
mechanisms in the progression of HF
• Chronic activation of the sympathetic
nervous system and the renin-
angiotensin-aldosterone axis is
associated with remodeling of cardiac
tissue, characterized by:
• loss of myocytes.
• Hypertrophy.
• fibrosis.
Sequelae of Heart Failure
Right Heart Failure
Systemic venous
congestion:
1. distended neck
veins.
2. enlarged liver.
3. peripheral
edema.
4. ascites.
Left Heart Failure
• Pulmonary
edema
(Dyspnea)
Symptoms of Heart Failure
Compensated (Asymptomatic)
Uncompensated (Symptomatic)
• Fatigue
• Dyspnea
• Orthopnea
(shortness of breath (dyspnea) which occurs when lying flat)
• Paroxysmal Nocturnal Dyspnea
• Ankle Edema
• Weight Gain
Adaptive mechanisms in heart failure
Compensated
Goals of pharmacologic intervention in HF
1. To alleviate symptoms.
2. Slow disease progression.
3. Improve survival.
Summary of drugs used to treat
heart failure.
ACE inhibitors (ACEI) - (Oral Meds)
The ACE inhibitor are the agents
of choice in HF
• Benazepril - Lotensin
• Captopril - Capoten
• Enalapril - Vasotec
• Fosinopril - Monopril
• Lisinopril – Prinivil
Angiotensin - converting enzyme inhibitors
Mechansim of action:
Angiotensin - converting enzyme inhibitors
Actions on the heart:
ACE inhibitors decrease:
1. Vascular resistance.
2. Venous tone.
3. Blood pressure.
preload andafterload
.
ACE inhibitors also blunt the usual
angiotensin II mediated increase in
epinephrine and aldosterone seen in HF.
Angiotensin - converting enzyme
inhibitors,
• Indications:
1. Single-agent therapy in patients who present with mild
dyspnea on exertion and do not show signs or symptoms
of volume overload.
2. In asymptomatic patients with an ejection fraction of
less than 35 % (left ventricular dysfunction).
(The term "ejection fraction" refers to the percentage of blood that's pumped out of a filled
ventricle with each heartbeat.)
1. Recent myocardial infarction also benefit from long-
term ACE inhibitor therapy.
2. In patients with all stages of left ventricular failure,
with and without symptoms, and therapy should be
initiated immediately after myocardial infarction.
• ACE inhibitors improve clinical signs and
symptoms in patients also receiving
thiazide or loop diuretics and/or digoxin.
• The use of ACE inhibitors in the treatment
of HF has significantly decreased both
morbidity and mortality.
Angiotensin - converting enzyme
inhibitors,
• Pharmacokinetics:
• Adequately but incompletely absorbed following oral
administration.
• The presence of food may decrease absorption, so they should be
taken on an empty stomach.
• ACE inhibitors are prodrugs that require activation by hydrolysis
via hepatic enzymes (Except for captopril ).
• Renal elimination of the active moiety is important (Except for
fosinopril) .
• t½ 2 to 12 hours.
Angiotensin - converting enzyme
inhibitors,
• Adverse effects:
• postural hypotension,
• renal insufficiency,
• hyperkalemia,
• Angioedema.
• persistent dry cough.
• ACE inhibitors should not be used in pregnant women,
because they are fetotoxic
Angiotensin receptor blockers, &
related agents
• losartan (AT1 receptor-blockers) appear to
have similar but more limited beneficial
effects.
• Angiotensin receptor blockers should be
considered in patients intolerant of ACE
inhibitors.
Angiotensin receptor blockers, &
related agents (ARBs)
• extremely potent competitive antagonists of the angiotensin type
1 (AT1)receptor.
• ARBs have the advantage of more complete blockade of
angiotensin action, because ACE inhibitors inhibit only one
enzyme responsible for the production of angiotensin II.
• ARBs do not affect bradykinin levels.
Angiotensin receptor blockers, &
related agents (ARBs)
• All the ARBs are approved for treatment of
hypertension based on their clinical efficacy in
lowering blood pressure and reducing the
morbidity and mortality associated with
hypertension.
• Their use in HF is as a substitute for ACE
inhibitors in those patients with severe cough
or angioedema.
Angiotensin receptor blockers, &
related agents (ARBs)
• Pharmacokinetics:
• orally active.
• require only once-a-day dosing.
• Losartan, the first approved member of the class,
differs from the others in that it undergoes extensive
first-pass hepatic metabolism, including conversion to
its active metabolite. The other drugs have inactive
metabolites.
• Elimination in the urine and feces
• All are highly plasma protein bound (greater than 90
percent)
Angiotensin receptor blockers, &
related agents (ARBs)
• Adverse effects:
• ARBs have an adverse effect profile similar to
that of ACE inhibitors.
• However, ARBs do not produce cough.
• ARBs are contraindicated in pregnancy.
β -adrenoceptor blockers
• Most patients with chronic heart failure respond
favorably to certain β blockers in spite of the fact
that these drugs can precipitate acute
decompensation of cardiac function.
• Studies with bisoprolol, carvedilol, and
metoprolol showed a reduction in mortality in
patients with stable severe heart failure.
• Suggested mechanisms include attenuation of
the adverse effects of high concentrations of
catecholamines.
β -adrenoceptor blockers
• Most patients with chronic heart failure respond
favorably to certain β blockers in spite of the fact
that these drugs can precipitate acute
decompensation of cardiac function. Studies with
bisoprolol, carvedilol, and metoprolol showed a
reduction in mortality in patients with stable
severe heart failure.
• Suggested mechanisms include attenuation of
the adverse effects of high concentrations of
catecholamines.
Diuretics
• Common thiazide diuretics
– Chlorothiazide (Diuril)
– Indapamide (Lozol)
– Metolazone (Zaroxolyn)
• Common loop diuretics
– Bumetanide (Bumex)
– Ethacrynic acid (Edecrin)
– Furosemide (Lasix)
• Common potassium-sparing diuretics
– Amiloride (Midamor)
– Eplerenone (Inspra)
– Spironolactone (Aldactone
Diuretics
• Their major mechanism of action in heart failure is to
reduce venous pressure and ventricular preload. This
results in reduction of edema and its symptoms, and
reduction of cardiac size, which leads to improved pump
efficiency.
• Loop diuretics, such as furosemide (Lasix), block the Na+-
K+ - 2Cl
_
in the ascending limb of the loop of Henle. loop diuretics are
still part of the mainstay of therapy for CHF despite these
potential problems
• Spironolactone and eplerenone, the aldosterone antagonist
diuretics have the additional benefit of decreasing
morbidity and mortality in patients with severe heart
failure.
Vasodilators
• The vasodilators are effective in acute
heart failure because they provide a
reduction in preload (through
venodilation), or reduction in afterload
(through arteriolar dilation), or both.
Some evidence suggests that long-term
use of hydralazine and isosorbide
dinitrate can also reduce damaging
remodeling of the heart.
Drug Therapy - Digitalis
Glycosides
Action: Increases the
force and velocity of
myocardial
contraction
Digoxin (Lanoxin)
Digitoxin
(Crystodigin)
Purple foxglove - digitalis
Drug Considerations - Digitalis
Glycosides
• Vasoconstrictor Interaction: concurrent
use may increase the risk of cardiac
arrhythmias – avoid if possible
• Oral Manifestations: increased gag reflex,
nausea/vomiting
• Other Considerations:
– macrolide antibiotics (erythromycin) can
increase bioavailability of DG resulting in
toxicity; avoid these drugs
– watch for DG toxicity (tachycardia, N/V,
hypersalivation, vision changes, fatigue, HA)
DIGITALIS
• Introduction
• Digitalis is the genus name for the family of
plants that provide most of the medically useful
cardiac glycosides, eg, digoxin.
Inotropic Definition
• Force of myocardial contraction
• Positive inotropic drug: increases force
of contractions
• Negative inotropic drug: decreases
force of contraction
Digitalis Glycosides
• Increase force of myocardial
contraction.
• Increase myocardial contractility
causing more complete emptying.
• Causes improved heart’s pumping
ability
Pharmacokinetics
A. Absorption:
• 65-80% absorbed after oral administration.
B. Distribution:
• widely distributed to tissues, including the
central nervous system.
C. Metabolism:
• Small amount in liver & GI flora.
D. Excretion:
• Unchanged drug from kidneys
Pharmacodynamics
• At the molecular level, all therapeutically useful
cardiac glycosides inhibit Na+/K+ ATPase, the
membrane-bound transporter often called the
sodium pump.
Pharmacodynamics
• Cardiac glycosides increase contraction
of the cardiac sarcomere , by increasing
the free calcium concentration in the
vicinity of the contractile proteins during
systole.
1. An increase of intracellular sodium
concentration because of Na+/K+ ATPase
inhibition.
2. Relative reduction of calcium expulsion
from the cell by the sodium-calcium
exchanger caused by the increase in
intracellular sodium, ( contractile force,
Clinical Use
1. Congestive heart failure:
2. Cardiac arrhythmias: ( atrial
fibrillation )
Toxicity
1. Gastrointestinal
– Salivation
– Anorexia
– Nausea
– Vomiting
– Diarrhea
2. CNS
– Headache
– Visual disturbances
characteristic (green
yellow halos around
bright objects).
– Fatigue
– Drowsiness
• Digitalis is a fat-soluble steroid that
crosses the blood-brain barrier and
enhances vagal tone
• This action involves:
• sensitization of the baroreceptors.
• central vagal stimulation.
Toxicity
3. Cardiac
• Atrioventricular (AV) block.
• Excessive slowing of the
heart
• supraventricular and
ventricular tachycardia.
4. Miscellaneous
• Excessive urination
• Because cholinergic
innervation is much richer
in the atria.
• Enhanced vagal nerve
activity causes a decrease
in sinoatrial beating rate
and velocity of
atrioventricular
conduction.
• facilitation of muscarinic
transmission at the cardiac
muscle cell
Treatment for digitalis toxicity:
• Mild cases that respond to simply
stopping the drug temporarily.
• In severe cases the use of
antidigoxin drug, antidote is given
intravenously and inactivates
digoxin in life-threatening situations.
Other positive inotropic drugs
Dobutamine.
• The selective β1 agonist that has been most
widely used in patients with heart failure.
• Tachycardia and an increase in myocardial
oxygen consumption have been reported.
Therefore, the potential for producing angina or
arrhythmias in patients with coronary artery
disease must be considered.
• Dopamine has also been used in acute heart
failure and may be particularly helpful if there is a
need to raise blood pressure.
Drugs without positive inotropic effects
• Paradoxically, these agents-not positive
inotropic drugs-are the first-line
therapies for chronic heart failure.
• In acute failure, diuretics and
vasodilators play important roles.
Beneficial effects of pharmacologic intervention in
HF
1. Reduction of the load on the
myocardium.
2. Decreased extracellular fluid volume.
3. Improved cardiac contractility.
4. Slowing of the rate of cardiac
remodeling.
•
IMPLICATIONS FOR
DENTISTRY
Stress Factors
 -Eliminate needless stress for cardiac patients, especially
anxiety or pain associated with dental procedures. Patients
being treated for heart failure possess limited cardiac function.
 -These patients are at special risk in stressful situations
because stress puts a greater workload on the heart and
stimulates the release of endogenous catecholamines.
 -catecholamines increase the risk of digoxin-induced
arrhythmias.
 -Fear and apprehension may also increase the likelihood of
adverse CNS reactions to digoxin.
 -One practical conclusion is that antianxiety therapy or
analgesics should be used preemptively if emotional stress or
pain is likely.
Drug Interactions
 The use of catecholamines in local anesthetic injections for
patients taking digoxin is not contraindicated but should be
approached with special caution.
 Proper injection technique to avoid intravascular injection
should be followed.
 Many factors influence the decision to use vasoconstrictors in
local anesthetic solutions, including the ability to achieve
adequate anesthesia without vasoconstrictors and the volume
of anesthetic solution required.
 The chief danger of sympathomimetic vasoconstrictors for
patients taking digoxin is that the combination of drugs
increases the risk of cardiac arrhythmias if significant amounts
of vasoconstrictor enter the vascular space
- The use of gingival retraction cords impregnated with
epinephrine is not recommended in patients taking digoxin.
Cardiac disease in general is a contraindication for their use.
Considerable amounts of vasoconstrictor may be absorbed
systemically from these retraction cords, and the possibility of
cardiac arrhythmias developing is significant. If hemostatic
retraction cords are to be used in patients who are on digoxin,
the cords should be impregnated with an astringent in place
of a vasoconstrictor.
• Antisialagogues such as atropine and
methantheline should not be used in patients
taking digoxin because they tend to reduce
the effects of digoxin.
• Muscarinic receptor agonists such as
pilocarpine enhance the effect of digoxin on
the SA node, the atria, and the AV node.
• Excessive salivation may be a sign of toxicity
owing to digoxin.
Antibiotic therapy may alter the intestinal flora
and, in so doing, increase the absorption of
digoxin in patients whose gastrointestinal flora
metabolizes digoxin.
Erythromycin, and presumably other macrolides,
has been shown to have this effect.
Tetracyclines also seem to interact through this
mechanism.
Thank you

More Related Content

What's hot

20 Saxena Acute Renal Failure
20 Saxena   Acute Renal Failure20 Saxena   Acute Renal Failure
20 Saxena Acute Renal FailureDang Thanh Tuan
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
Dr. Prem Mohan Jha
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
drriyaz95
 
Acute kidney injury
Acute kidney injury Acute kidney injury
Acute kidney injury
anoop k r
 
Acute kidney injury: Perioperative implications
Acute kidney injury: Perioperative implicationsAcute kidney injury: Perioperative implications
Acute kidney injury: Perioperative implications
Abhijit Nair
 
31 derebail acute renal failure
31 derebail   acute renal failure31 derebail   acute renal failure
31 derebail acute renal failureDang Thanh Tuan
 
Acute kidney injury (AKI)
Acute kidney injury (AKI)Acute kidney injury (AKI)
Acute kidney injury (AKI)
Wail Eldukali
 
Acute kidney injury in pediatrics
Acute kidney injury in pediatricsAcute kidney injury in pediatrics
Acute kidney injury in pediatrics
Virendra Hindustani
 
Acute renal disease
Acute renal diseaseAcute renal disease
Acute renal disease
SHARIQUE RAZA
 
Acute kidney Injury
Acute kidney InjuryAcute kidney Injury
Acute kidney Injury
Rajanna Sreedhara
 
Approach to a case of aki
Approach to a case of akiApproach to a case of aki
Approach to a case of aki
Vamsa Vardhan
 
10 Palevsky Acute Renal Failure
10 Palevsky   Acute Renal Failure10 Palevsky   Acute Renal Failure
10 Palevsky Acute Renal Failureguest2379201
 
Acute kidney injury prevention new microsoft power po.int presentation
Acute kidney injury prevention new microsoft power po.int presentationAcute kidney injury prevention new microsoft power po.int presentation
Acute kidney injury prevention new microsoft power po.int presentation
Ayman Seddik
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
kidney injury-Hamisi Mkindi,Presentation
kidney injury-Hamisi Mkindi,Presentationkidney injury-Hamisi Mkindi,Presentation
kidney injury-Hamisi Mkindi,Presentation
Mkindi Mkindi
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
Jyoti Kathwal
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
IPMS- KMU KPK PAKISTAN
 
Aki
AkiAki
anaesthesia in chronic kidney disease
anaesthesia in chronic kidney diseaseanaesthesia in chronic kidney disease
anaesthesia in chronic kidney disease
sarmistha panigrahi
 

What's hot (20)

20 Saxena Acute Renal Failure
20 Saxena   Acute Renal Failure20 Saxena   Acute Renal Failure
20 Saxena Acute Renal Failure
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Acute kidney injury
Acute kidney injury Acute kidney injury
Acute kidney injury
 
Acute kidney injury: Perioperative implications
Acute kidney injury: Perioperative implicationsAcute kidney injury: Perioperative implications
Acute kidney injury: Perioperative implications
 
31 derebail acute renal failure
31 derebail   acute renal failure31 derebail   acute renal failure
31 derebail acute renal failure
 
Acute kidney injury (AKI)
Acute kidney injury (AKI)Acute kidney injury (AKI)
Acute kidney injury (AKI)
 
Acute kidney injury in pediatrics
Acute kidney injury in pediatricsAcute kidney injury in pediatrics
Acute kidney injury in pediatrics
 
Acute renal disease
Acute renal diseaseAcute renal disease
Acute renal disease
 
Acute renal failure (2)
Acute renal failure (2)Acute renal failure (2)
Acute renal failure (2)
 
Acute kidney Injury
Acute kidney InjuryAcute kidney Injury
Acute kidney Injury
 
Approach to a case of aki
Approach to a case of akiApproach to a case of aki
Approach to a case of aki
 
10 Palevsky Acute Renal Failure
10 Palevsky   Acute Renal Failure10 Palevsky   Acute Renal Failure
10 Palevsky Acute Renal Failure
 
Acute kidney injury prevention new microsoft power po.int presentation
Acute kidney injury prevention new microsoft power po.int presentationAcute kidney injury prevention new microsoft power po.int presentation
Acute kidney injury prevention new microsoft power po.int presentation
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
kidney injury-Hamisi Mkindi,Presentation
kidney injury-Hamisi Mkindi,Presentationkidney injury-Hamisi Mkindi,Presentation
kidney injury-Hamisi Mkindi,Presentation
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Aki
AkiAki
Aki
 
anaesthesia in chronic kidney disease
anaesthesia in chronic kidney diseaseanaesthesia in chronic kidney disease
anaesthesia in chronic kidney disease
 

Similar to Cardiovascular

Ant ihypertensive
Ant ihypertensiveAnt ihypertensive
Ant ihypertensive
Monika Devi NR
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
Subramani Parasuraman
 
lecture-3 hypertantion.pdf
lecture-3 hypertantion.pdflecture-3 hypertantion.pdf
lecture-3 hypertantion.pdf
Obsa2
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
ajaykumarbp
 
Pharmacological management of heart failure
Pharmacological management of heart failurePharmacological management of heart failure
Pharmacological management of heart failure
Naser Tadvi
 
pharmacologicalmanagementofheartfailure-171027075756.pdf
pharmacologicalmanagementofheartfailure-171027075756.pdfpharmacologicalmanagementofheartfailure-171027075756.pdf
pharmacologicalmanagementofheartfailure-171027075756.pdf
varu15
 
Recent Advances in CCF
Recent Advances in CCFRecent Advances in CCF
Recent Advances in CCF
Dr Ketan Asawalle
 
drugs used in high BP-anti-hypertensive drugs.pptx
drugs used in high BP-anti-hypertensive drugs.pptxdrugs used in high BP-anti-hypertensive drugs.pptx
drugs used in high BP-anti-hypertensive drugs.pptx
SajidHussain495712
 
Antihypertensivedrugs
Antihypertensivedrugs Antihypertensivedrugs
Antihypertensivedrugs
writngerrands
 
Anti hypertensive drugs.pptx
Anti hypertensive drugs.pptxAnti hypertensive drugs.pptx
Anti hypertensive drugs.pptx
Aymanshahzad4
 
HEART FAILURE: CONGESTIVE CARDIAC FAILURE
HEART FAILURE: CONGESTIVE CARDIAC FAILUREHEART FAILURE: CONGESTIVE CARDIAC FAILURE
HEART FAILURE: CONGESTIVE CARDIAC FAILURE
AbdullahAnsari755347
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptx
Ahad Ali
 
HYPERTENSION is a silent killer. prevention.pptx
HYPERTENSION is a silent killer. prevention.pptxHYPERTENSION is a silent killer. prevention.pptx
HYPERTENSION is a silent killer. prevention.pptx
santosh kadam
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensives
Dr. Marya Ahsan
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
ajaykumarbp
 
11241869.ppt
11241869.ppt11241869.ppt
11241869.ppt
ssuser497f37
 
Antihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptxAntihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptx
SolimanAbuDalfa
 
Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...
Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...
Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...
Rahul Bhati
 

Similar to Cardiovascular (20)

Ant ihypertensive
Ant ihypertensiveAnt ihypertensive
Ant ihypertensive
 
Heart failure
Heart failureHeart failure
Heart failure
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
lecture-3 hypertantion.pdf
lecture-3 hypertantion.pdflecture-3 hypertantion.pdf
lecture-3 hypertantion.pdf
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Pharmacological management of heart failure
Pharmacological management of heart failurePharmacological management of heart failure
Pharmacological management of heart failure
 
pharmacologicalmanagementofheartfailure-171027075756.pdf
pharmacologicalmanagementofheartfailure-171027075756.pdfpharmacologicalmanagementofheartfailure-171027075756.pdf
pharmacologicalmanagementofheartfailure-171027075756.pdf
 
Recent Advances in CCF
Recent Advances in CCFRecent Advances in CCF
Recent Advances in CCF
 
drugs used in high BP-anti-hypertensive drugs.pptx
drugs used in high BP-anti-hypertensive drugs.pptxdrugs used in high BP-anti-hypertensive drugs.pptx
drugs used in high BP-anti-hypertensive drugs.pptx
 
Antihypertensivedrugs
Antihypertensivedrugs Antihypertensivedrugs
Antihypertensivedrugs
 
Anti hypertensive drugs.pptx
Anti hypertensive drugs.pptxAnti hypertensive drugs.pptx
Anti hypertensive drugs.pptx
 
HEART FAILURE: CONGESTIVE CARDIAC FAILURE
HEART FAILURE: CONGESTIVE CARDIAC FAILUREHEART FAILURE: CONGESTIVE CARDIAC FAILURE
HEART FAILURE: CONGESTIVE CARDIAC FAILURE
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptx
 
HYPERTENSION is a silent killer. prevention.pptx
HYPERTENSION is a silent killer. prevention.pptxHYPERTENSION is a silent killer. prevention.pptx
HYPERTENSION is a silent killer. prevention.pptx
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensives
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
 
11241869.ppt
11241869.ppt11241869.ppt
11241869.ppt
 
Antihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptxAntihypertensives Ch 1.pptx
Antihypertensives Ch 1.pptx
 
CHF.pptx
CHF.pptxCHF.pptx
CHF.pptx
 
Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...
Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...
Congestive Heart Failure Latest Guidelines and Recent Advances in Drug treatm...
 

Recently uploaded

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 

Recently uploaded (20)

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 

Cardiovascular

  • 2. What is Heart Failure? A symptom complex due to the inability of the heart to function efficiently as a pump - there is a disproportion between the hemodynamic demand and the capacity of the heart to handle the demand ( Supply ≠ Demand)
  • 3. Heart Failure • Heart failure occurs when cardiac output is inadequate to provide the oxygen needed by the body. • It is a highly lethal condition, with a 5- year mortality rate conventionally said to be about 50%. • The most common cause of heart failure is coronary artery disease.
  • 4. If Heart does not contract well (systolic HF) traffic (blood) piles up before the heart (lungs and periphery).
  • 5. Role of physiologic compensatory mechanisms in the progression of HF • Chronic activation of the sympathetic nervous system and the renin- angiotensin-aldosterone axis is associated with remodeling of cardiac tissue, characterized by: • loss of myocytes. • Hypertrophy. • fibrosis.
  • 6. Sequelae of Heart Failure Right Heart Failure Systemic venous congestion: 1. distended neck veins. 2. enlarged liver. 3. peripheral edema. 4. ascites. Left Heart Failure • Pulmonary edema (Dyspnea)
  • 7. Symptoms of Heart Failure Compensated (Asymptomatic) Uncompensated (Symptomatic) • Fatigue • Dyspnea • Orthopnea (shortness of breath (dyspnea) which occurs when lying flat) • Paroxysmal Nocturnal Dyspnea • Ankle Edema • Weight Gain
  • 8. Adaptive mechanisms in heart failure Compensated
  • 9. Goals of pharmacologic intervention in HF 1. To alleviate symptoms. 2. Slow disease progression. 3. Improve survival.
  • 10. Summary of drugs used to treat heart failure.
  • 11.
  • 12.
  • 13. ACE inhibitors (ACEI) - (Oral Meds) The ACE inhibitor are the agents of choice in HF • Benazepril - Lotensin • Captopril - Capoten • Enalapril - Vasotec • Fosinopril - Monopril • Lisinopril – Prinivil
  • 14. Angiotensin - converting enzyme inhibitors Mechansim of action:
  • 15. Angiotensin - converting enzyme inhibitors Actions on the heart: ACE inhibitors decrease: 1. Vascular resistance. 2. Venous tone. 3. Blood pressure. preload andafterload . ACE inhibitors also blunt the usual angiotensin II mediated increase in epinephrine and aldosterone seen in HF.
  • 16. Angiotensin - converting enzyme inhibitors, • Indications: 1. Single-agent therapy in patients who present with mild dyspnea on exertion and do not show signs or symptoms of volume overload. 2. In asymptomatic patients with an ejection fraction of less than 35 % (left ventricular dysfunction). (The term "ejection fraction" refers to the percentage of blood that's pumped out of a filled ventricle with each heartbeat.) 1. Recent myocardial infarction also benefit from long- term ACE inhibitor therapy. 2. In patients with all stages of left ventricular failure, with and without symptoms, and therapy should be initiated immediately after myocardial infarction.
  • 17. • ACE inhibitors improve clinical signs and symptoms in patients also receiving thiazide or loop diuretics and/or digoxin. • The use of ACE inhibitors in the treatment of HF has significantly decreased both morbidity and mortality.
  • 18. Angiotensin - converting enzyme inhibitors, • Pharmacokinetics: • Adequately but incompletely absorbed following oral administration. • The presence of food may decrease absorption, so they should be taken on an empty stomach. • ACE inhibitors are prodrugs that require activation by hydrolysis via hepatic enzymes (Except for captopril ). • Renal elimination of the active moiety is important (Except for fosinopril) . • t½ 2 to 12 hours.
  • 19. Angiotensin - converting enzyme inhibitors, • Adverse effects: • postural hypotension, • renal insufficiency, • hyperkalemia, • Angioedema. • persistent dry cough. • ACE inhibitors should not be used in pregnant women, because they are fetotoxic
  • 20. Angiotensin receptor blockers, & related agents • losartan (AT1 receptor-blockers) appear to have similar but more limited beneficial effects. • Angiotensin receptor blockers should be considered in patients intolerant of ACE inhibitors.
  • 21. Angiotensin receptor blockers, & related agents (ARBs) • extremely potent competitive antagonists of the angiotensin type 1 (AT1)receptor. • ARBs have the advantage of more complete blockade of angiotensin action, because ACE inhibitors inhibit only one enzyme responsible for the production of angiotensin II. • ARBs do not affect bradykinin levels.
  • 22. Angiotensin receptor blockers, & related agents (ARBs) • All the ARBs are approved for treatment of hypertension based on their clinical efficacy in lowering blood pressure and reducing the morbidity and mortality associated with hypertension. • Their use in HF is as a substitute for ACE inhibitors in those patients with severe cough or angioedema.
  • 23. Angiotensin receptor blockers, & related agents (ARBs) • Pharmacokinetics: • orally active. • require only once-a-day dosing. • Losartan, the first approved member of the class, differs from the others in that it undergoes extensive first-pass hepatic metabolism, including conversion to its active metabolite. The other drugs have inactive metabolites. • Elimination in the urine and feces • All are highly plasma protein bound (greater than 90 percent)
  • 24. Angiotensin receptor blockers, & related agents (ARBs) • Adverse effects: • ARBs have an adverse effect profile similar to that of ACE inhibitors. • However, ARBs do not produce cough. • ARBs are contraindicated in pregnancy.
  • 25. β -adrenoceptor blockers • Most patients with chronic heart failure respond favorably to certain β blockers in spite of the fact that these drugs can precipitate acute decompensation of cardiac function. • Studies with bisoprolol, carvedilol, and metoprolol showed a reduction in mortality in patients with stable severe heart failure. • Suggested mechanisms include attenuation of the adverse effects of high concentrations of catecholamines.
  • 26. β -adrenoceptor blockers • Most patients with chronic heart failure respond favorably to certain β blockers in spite of the fact that these drugs can precipitate acute decompensation of cardiac function. Studies with bisoprolol, carvedilol, and metoprolol showed a reduction in mortality in patients with stable severe heart failure. • Suggested mechanisms include attenuation of the adverse effects of high concentrations of catecholamines.
  • 27. Diuretics • Common thiazide diuretics – Chlorothiazide (Diuril) – Indapamide (Lozol) – Metolazone (Zaroxolyn) • Common loop diuretics – Bumetanide (Bumex) – Ethacrynic acid (Edecrin) – Furosemide (Lasix) • Common potassium-sparing diuretics – Amiloride (Midamor) – Eplerenone (Inspra) – Spironolactone (Aldactone
  • 28. Diuretics • Their major mechanism of action in heart failure is to reduce venous pressure and ventricular preload. This results in reduction of edema and its symptoms, and reduction of cardiac size, which leads to improved pump efficiency. • Loop diuretics, such as furosemide (Lasix), block the Na+- K+ - 2Cl _ in the ascending limb of the loop of Henle. loop diuretics are still part of the mainstay of therapy for CHF despite these potential problems • Spironolactone and eplerenone, the aldosterone antagonist diuretics have the additional benefit of decreasing morbidity and mortality in patients with severe heart failure.
  • 29. Vasodilators • The vasodilators are effective in acute heart failure because they provide a reduction in preload (through venodilation), or reduction in afterload (through arteriolar dilation), or both. Some evidence suggests that long-term use of hydralazine and isosorbide dinitrate can also reduce damaging remodeling of the heart.
  • 30. Drug Therapy - Digitalis Glycosides Action: Increases the force and velocity of myocardial contraction Digoxin (Lanoxin) Digitoxin (Crystodigin) Purple foxglove - digitalis
  • 31. Drug Considerations - Digitalis Glycosides • Vasoconstrictor Interaction: concurrent use may increase the risk of cardiac arrhythmias – avoid if possible • Oral Manifestations: increased gag reflex, nausea/vomiting • Other Considerations: – macrolide antibiotics (erythromycin) can increase bioavailability of DG resulting in toxicity; avoid these drugs – watch for DG toxicity (tachycardia, N/V, hypersalivation, vision changes, fatigue, HA)
  • 32. DIGITALIS • Introduction • Digitalis is the genus name for the family of plants that provide most of the medically useful cardiac glycosides, eg, digoxin.
  • 33. Inotropic Definition • Force of myocardial contraction • Positive inotropic drug: increases force of contractions • Negative inotropic drug: decreases force of contraction
  • 34. Digitalis Glycosides • Increase force of myocardial contraction. • Increase myocardial contractility causing more complete emptying. • Causes improved heart’s pumping ability
  • 35. Pharmacokinetics A. Absorption: • 65-80% absorbed after oral administration. B. Distribution: • widely distributed to tissues, including the central nervous system. C. Metabolism: • Small amount in liver & GI flora. D. Excretion: • Unchanged drug from kidneys
  • 36. Pharmacodynamics • At the molecular level, all therapeutically useful cardiac glycosides inhibit Na+/K+ ATPase, the membrane-bound transporter often called the sodium pump.
  • 37. Pharmacodynamics • Cardiac glycosides increase contraction of the cardiac sarcomere , by increasing the free calcium concentration in the vicinity of the contractile proteins during systole. 1. An increase of intracellular sodium concentration because of Na+/K+ ATPase inhibition. 2. Relative reduction of calcium expulsion from the cell by the sodium-calcium exchanger caused by the increase in intracellular sodium, ( contractile force,
  • 38. Clinical Use 1. Congestive heart failure: 2. Cardiac arrhythmias: ( atrial fibrillation )
  • 39. Toxicity 1. Gastrointestinal – Salivation – Anorexia – Nausea – Vomiting – Diarrhea 2. CNS – Headache – Visual disturbances characteristic (green yellow halos around bright objects). – Fatigue – Drowsiness • Digitalis is a fat-soluble steroid that crosses the blood-brain barrier and enhances vagal tone • This action involves: • sensitization of the baroreceptors. • central vagal stimulation.
  • 40. Toxicity 3. Cardiac • Atrioventricular (AV) block. • Excessive slowing of the heart • supraventricular and ventricular tachycardia. 4. Miscellaneous • Excessive urination • Because cholinergic innervation is much richer in the atria. • Enhanced vagal nerve activity causes a decrease in sinoatrial beating rate and velocity of atrioventricular conduction. • facilitation of muscarinic transmission at the cardiac muscle cell
  • 41. Treatment for digitalis toxicity: • Mild cases that respond to simply stopping the drug temporarily. • In severe cases the use of antidigoxin drug, antidote is given intravenously and inactivates digoxin in life-threatening situations.
  • 43. Dobutamine. • The selective β1 agonist that has been most widely used in patients with heart failure. • Tachycardia and an increase in myocardial oxygen consumption have been reported. Therefore, the potential for producing angina or arrhythmias in patients with coronary artery disease must be considered. • Dopamine has also been used in acute heart failure and may be particularly helpful if there is a need to raise blood pressure.
  • 44. Drugs without positive inotropic effects • Paradoxically, these agents-not positive inotropic drugs-are the first-line therapies for chronic heart failure. • In acute failure, diuretics and vasodilators play important roles.
  • 45. Beneficial effects of pharmacologic intervention in HF 1. Reduction of the load on the myocardium. 2. Decreased extracellular fluid volume. 3. Improved cardiac contractility. 4. Slowing of the rate of cardiac remodeling.
  • 47. Stress Factors  -Eliminate needless stress for cardiac patients, especially anxiety or pain associated with dental procedures. Patients being treated for heart failure possess limited cardiac function.  -These patients are at special risk in stressful situations because stress puts a greater workload on the heart and stimulates the release of endogenous catecholamines.  -catecholamines increase the risk of digoxin-induced arrhythmias.  -Fear and apprehension may also increase the likelihood of adverse CNS reactions to digoxin.  -One practical conclusion is that antianxiety therapy or analgesics should be used preemptively if emotional stress or pain is likely.
  • 48. Drug Interactions  The use of catecholamines in local anesthetic injections for patients taking digoxin is not contraindicated but should be approached with special caution.  Proper injection technique to avoid intravascular injection should be followed.  Many factors influence the decision to use vasoconstrictors in local anesthetic solutions, including the ability to achieve adequate anesthesia without vasoconstrictors and the volume of anesthetic solution required.  The chief danger of sympathomimetic vasoconstrictors for patients taking digoxin is that the combination of drugs increases the risk of cardiac arrhythmias if significant amounts of vasoconstrictor enter the vascular space
  • 49. - The use of gingival retraction cords impregnated with epinephrine is not recommended in patients taking digoxin. Cardiac disease in general is a contraindication for their use. Considerable amounts of vasoconstrictor may be absorbed systemically from these retraction cords, and the possibility of cardiac arrhythmias developing is significant. If hemostatic retraction cords are to be used in patients who are on digoxin, the cords should be impregnated with an astringent in place of a vasoconstrictor.
  • 50. • Antisialagogues such as atropine and methantheline should not be used in patients taking digoxin because they tend to reduce the effects of digoxin. • Muscarinic receptor agonists such as pilocarpine enhance the effect of digoxin on the SA node, the atria, and the AV node. • Excessive salivation may be a sign of toxicity owing to digoxin.
  • 51. Antibiotic therapy may alter the intestinal flora and, in so doing, increase the absorption of digoxin in patients whose gastrointestinal flora metabolizes digoxin. Erythromycin, and presumably other macrolides, has been shown to have this effect. Tetracyclines also seem to interact through this mechanism.